Clinical trials: Cholangiocarcinoma, Intrahepatic
Intrahepatic Cholangiocarcinoma
Regional or Extend LymphAdenectomy During Resection of Intrahepatic Cholangiocarcinoma
Intrahepatic cholangiocarcinoma (ICC) is one of the common malignant tumors. Lymph node metastasis is an important factor affecting the poor prognosis of intrahepatic cholangiocarcinoma.
- Trial name
- NCT04078230
- Testing
- Extend LymphAdenectomy
- Where
- 13 sites in United States, China
- Volunteers
- 168 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Hepatocellular Carcinoma, Intrahepatic Cholangiocarcinoma
Melphalan for Use With the Hepatic Delivery System Treatment in Patients With Unresectable Hepatocellular Carcinoma or Intra Hepatic Cholangiocarcinoma
This is a two arm, open label, multi-center, Phase 2 study to evaluate the efficacy and safety of Melphalan/HDS in patients with unresectable Hepatocellular Carcinoma (HCC) or Intra Hepatic Cholangiocarcinoma (ICC) confined to…
- Trial name
- NCT02415036
- Testing
- Delcath Hepatic Delivery System, Melphalan
- Where
- 3 sites in Germany
- Volunteers
- 17 people
- Sponsor
- Delcath Systems Inc.
Intrahepatic Cholangiocarcinoma
Second Line Therapy for Advanced Intrahepatic Cholangiocarcinoma
This is a prospective, Two-arm, comparative, randomized, controlled phase II trial, to explore the efficacy and safety of Regorafenib and HAIC vs. FOLFOX as Second Line Therapy for Advanced Intrahepatic Cholangiocarcinoma.
- Trial name
- NCT05535647
- Testing
- Regorafenib and HAIC, FOLFOX
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Cholangiocarcinoma, Intrahepatic
Adjuvant PD-1 Antibody in Combination With Capecitabine for Patients With ICC at High-Risk of Postoperative Recurrence
The purpose of the study is to observe the effect of PD-1 Antibody（Tislelizumab） Combined With Capecitabine as Adjuvant Therapy to Prevent the Recurrence in High-risk Patients With Cholangiocarcinoma After Curative Resection.
- Trial name
- NCT04782804
- Testing
- Capecitabine, PD-1 Antibody（Tislelizumab）
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Fudan University
Intrahepatic Cholangiocarcinoma
HAIC Plus Targeted Therapy and/or PD-1 Inhibitors for Unresectable Intrahepatic Cholangiocarcinoma
Intrahepatic cholangiocarcinoma (ICC) is associated with poor prognosis. This study aims to explore the efficacy and safety FOLFOX-HAIC in combination with targeted therapy and/or PD-1 inhibitors for patients with initially…
- Trial name
- NCT05489692
- Testing
- hepatic arterial infusion chemotherapy (HAIC) of oxaliplatin, fluorouracil, and leucovorin (FOLFOX)
- Where
- China
- Volunteers
- 43 people
- Sponsor
- Sun Yat-sen University
Intrahepatic Cholangiocarcinoma
HAIC Combined With Tislelizumab and Apatinib for Unresectable Intrahepatic Cholangiocarcinoma
Primary liver cancer is the sixth most common cancer worldwide, including hepatocellular carcinoma and intrahepatic cholangiocarcinoma, of which intrahepatic cholangiocarcinoma accounts for 10%-15%.
- Trial name
- NCT05290116
- Testing
- HAIC Combined with Tislelizumab and Apatinib
- Where
- China
- Volunteers
- 17 people
- Sponsor
- Yunfei Yuan
Intrahepatic Cholangiocarcinoma
A Single-arm Study of Gemcitabine, Cisplatin, and Nab-Paclitaxel as Neoadjuvant Therapy for Resectable Oncologically High-Risk IHCC in Korea
1. Phase of Development: II 2. Patient Population: Resectable Oncologically High-Risk Intrahepatic Cholangiocarcinoma 3. Estimated Number of Patients: 34 patients 4.
- Trial name
- NCT04546828
- Testing
- Gemcitabine, Cisplatin, and Nab-Paclitaxe
- Sponsor
- Samsung Medical Center
Hepatocellular Carcinoma, Cholangiocarcinoma, Intrahepatic
Study of GNS561 in Patients With Liver Cancer
This is a first in human, open-label dose escalation study to investigate the safety, tolerability and pharmacokinetics of GNS561 in patients Primary and Secondary liver cancer
- Trial name
- NCT03316222
- Testing
- GNS561
- Where
- 5 sites in United States, Belgium and 1 more
- Volunteers
- 50 people
- Sponsor
- Genoscience Pharma
Intrahepatic Cholangiocarcinoma
Establishment of Scoring Model for Early and Differential Diagnosis of Intrahepatic Cholangiocarcinoma
The purpose of this study is to develop and validate a radiological nomogram including radiological characteristics, clinical risk factors, and medical history.
- Trial name
- NCT05327907
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Qilu Hospital of Shandong University
Intrahepatic Cholangiocarcinoma
GP Chemotherapy in Combination With Tislelizumab and Ociperlimab as First-line Treatment in Advanced BTC
This is an open label, multi-center, phaseⅡstudy to evaluate the efficacy and safety of GP (Gemcitabine/Cisplatin) in combination with Tislelizumab and Ociperlimab as first-line treatment in participants with unresectable…
- Trial name
- NCT05019677
- Testing
- GP+PD-1+Tight
- Where
- China
- Sponsor
- Fudan University
Bile Duct Cancer, Intrahepatic Cholangiocarcinoma
Percutaneous Hepatic Perfusion vs. Cisplatin/Gemcitabine in Patients With Intrahepatic Cholangiocarcinoma
This study will evaluate two groups of patients who have intrahepatic cholangiocarcinoma. Each group will receive induction treatment with Cisplatin and Gemcitabine per SOC for 4 treatment cycles.
- Trial name
- NCT03086993
- Testing
- Melphalan/HDS, Cisplatin and Gemcitabine
- Where
- 3 sites in United States
- Volunteers
- 295 people
- Sponsor
- Delcath Systems Inc.
Intrahepatic Cholangiocarcinoma
Sintilimab Combined With GEMOX ± IBI305 (Bevacizumab Biosimilar) Versus GEMOX in Advanced Intrahepatic Cholangiocarcinoma
A randomized controlled, phase II clinical trial is designed to compare the safety and efficacy of Sintilimab combined with GEMOX ± IBI305 and GEMOX as first-line therapy in advanced intrahepatic cholangiocarcinoma.
- Trial name
- NCT05251662
- Testing
- Sintilimab, IBI305, GEMOX
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Intrahepatic Cholangiocarcinoma
TACE Combined With "Target Immune" Therapy for First-line Treatment in the Treatment of Intrahepatic Cholangiocarcinoma
This study is a prospective, multicenter, open, real-world clinical study. All eligible patients were assigned to experimental group (TACE combined with multi-target drugs and PD-1 inhibitors), and control group (conventional…
- Trial name
- NCT05247996
- Testing
- Transcatheter arterial chemoembolization, Multi-target Drug Therapy, Immunocheckpoint Inhibitor Therapy
- Volunteers
- 98 people
- Sponsor
- The Central Hospital of Lishui City
Stage III Intrahepatic Cholangiocarcinoma AJCC v7, Stage IIIA Gallbladder Cancer AJCC v7
Gemcitabine Hydrochloride, Cisplatin, and Nab-Paclitaxel in Treating Patients With Advanced or Metastatic Biliary Cancers
This phase II trial studies how well gemcitabine hydrochloride, cisplatin, and nab-paclitaxel (paclitaxel albumin-stabilized nanoparticle formulation) work in treating patients with biliary cancers (which includes the gallbladder…
- Conditions
- Stage III Intrahepatic Cholangiocarcinoma AJCC v7, Stage IIIA Gallbladder Cancer AJCC v7, Stage IIIB Gallbladder Cancer AJCC v7, Stage IVA Gallbladder Cancer AJCC v7
- Trial name
- NCT02392637
- Testing
- Cisplatin, Gemcitabine Hydrochloride, Laboratory Biomarker Analysis
- Where
- 3 sites in United States
- Volunteers
- 62 people
- Sponsor
- M.D. Anderson Cancer Center
Intrahepatic Cholangiocarcinoma
Routine Lymphadenectomy for Intrahepatic Cholangiocarcinoma
The role of routine lymphadenectomy (LND) in the surgical treatment of intrahepatic cholangiocarcinoma (ICC) remains controversial.
- Trial name
- LND for ICC (NCT03796819)
- Testing
- lymphadenectomy
- Where
- China
- Volunteers
- 260 people
- Sponsor
- First Affiliated Hospital Xi'an Jiaotong University
Metastatic Colon Cancer, Liver Cancer
Hepatic Artery Infusion (HAI) Program at Duke University
The Duke HAI program was implemented in November 2018 and treated 30 patients in its first 17 months using the Medtronic Synchromed II device (only commercially available device suitable for HAI for cancer patients).
- Conditions
- Metastatic Colon Cancer, Liver Cancer, Intrahepatic Cholangiocarcinoma
- Trial name
- NCT04511793
- Testing
- Medtronic Synchromed II pump
- Sponsor
- Michael Lidsky, M.D.
Intrahepatic Cholangiocarcinoma
Anti-PD1 Antibody Toripalimab Combined With Gemox as First-line Therapy in Late-stage Intrahepatic Cholangiocarcinoma
To explore the objective response rate and safety of toripalimab combined with Gemox in the first-line treatment of progressive, metastatic or unresectable advanced ICC.
- Trial name
- NCT04961788
- Testing
- Gemox combimed PD1 antibody
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Shanghai Zhongshan Hospital
Intrahepatic Cholangiocarcinoma
HAIC With FOLFOX Versus Systemic Chemotherapy With GP for Unresectable ICC
The purpose of this study is to evaluate the efficacy and safety of hepatic arterial infusion chemotherapy (HAIC) of oxaliplatin, 5-fluorouracil and leucovorin compared systemic chemotherapy of gemcitabine and cisplatin in…
- Trial name
- NCT04961970
- Testing
- oxaliplatin , fluorouracil, and leucovorin, gemcitabine and cisplatin
- Where
- China
- Volunteers
- 188 people
- Sponsor
- Shi Ming
Cholangiocarcinoma, Intrahepatic
Combined Therapy Using Oxaliplatin and Gemcitabine Chemotherapy, Lenvatinib and PD1 Antibody (JS001) for Patients With Advanced and Unresectable Intrahepatic Cholangiocarcinoma
In this phase 2 study, the investigators aim to evaluate the effects and safety of combined therapy using oxaliplatin and gemcitabine chemotherapy, Lenvatinib and immune checkpoint inhibitor PD-1 antibody (JS001) for patients…
- Trial name
- NCT03951597
- Testing
- combined therapy using oxaliplatin and gemcitabine chemotherapy, Lenvatinib and PD1 antibody (JS001)
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Shanghai Zhongshan Hospital
Intrahepatic Cholangiocarcinoma
A Trial of Famitinib in Patients With Failure of First-Line Treatment For Intrahepatic Cholangiocarcinoma
This is a single-arm, open-label, multi-center Phase II clinical trial intended to observe and evaluate the efficacy and safety of famitinib malate in treating iCCA(Intrahepatic Cholangiocarcinoma ) patients with FGFR2 genetic…
- Trial name
- NCT04479904
- Testing
- Famitinib
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.